These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

433 related items for PubMed ID: 27266233

  • 1. Quality of Life Achieved by Carboplatin Plus Etoposide as Third-Line Chemotherapy Compared with Best Supportive Care in Non-Small Cell Lung Cancer Stage IIIB/IV.
    Maneechawakajorn J, Hathaisanguan S.
    J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S175-81. PubMed ID: 27266233
    [Abstract] [Full Text] [Related]

  • 2. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.
    Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D.
    J Clin Oncol; 2000 Feb; 18(3):623-31. PubMed ID: 10653877
    [Abstract] [Full Text] [Related]

  • 3. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
    Socinski MA, Schell MJ, Bakri K, Peterman A, Lee JH, Unger P, Yates S, Hudgens S, Kies MS.
    Cancer; 2002 Sep 15; 95(6):1265-73. PubMed ID: 12216094
    [Abstract] [Full Text] [Related]

  • 4. Quality of life in advanced non-small cell lung cancer receiving chemotherapy of platinum combination in old versus new standard chemotherapy regimen.
    Maneechawakajorn J, Suksuperm J.
    J Med Assoc Thai; 2014 Nov 15; 97 Suppl 11():S69-75. PubMed ID: 25509698
    [Abstract] [Full Text] [Related]

  • 5. Platinum/etoposide therapy in non-small cell lung cancer.
    Bonomi P.
    Oncology; 1992 Nov 15; 49 Suppl 1():43-50. PubMed ID: 1323811
    [Abstract] [Full Text] [Related]

  • 6. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study Group.
    Helsing M, Bergman B, Thaning L, Hero U.
    Eur J Cancer; 1998 Jun 15; 34(7):1036-44. PubMed ID: 9849452
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
    Reynolds C, Barrera D, Jotte R, Spira AI, Weissman C, Boehm KA, Pritchard S, Asmar L.
    J Thorac Oncol; 2009 Dec 15; 4(12):1537-43. PubMed ID: 19887966
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer].
    Li DX, Chen XB.
    Ai Zheng; 2002 Apr 15; 21(4):412-5. PubMed ID: 12452023
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer.
    Thongprasert S, Permsuwan U, Ruengorn C, Charoentum C, Chewaskulyong B.
    Asia Pac J Clin Oncol; 2011 Dec 15; 7(4):369-75. PubMed ID: 22151987
    [Abstract] [Full Text] [Related]

  • 12. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.
    Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S, Gitten R, Unger P, Lee J, Lee JH, Tynan M, Moore M, Kies MS.
    J Clin Oncol; 2002 Mar 01; 20(5):1335-43. PubMed ID: 11870177
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer.
    Socinski MA, Raju RN, Stinchcombe T, Kocs DM, Couch LS, Barrera D, Rousey SR, Choksi JK, Jotte R, Patt DA, Periman PO, Schlossberg HR, Weissman CH, Wang Y, Asmar L, Pritchard S, Bromund J, Peng G, Treat J, Obasaju CK.
    J Thorac Oncol; 2010 Dec 01; 5(12):1963-9. PubMed ID: 21102260
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer.
    Kim HJ, Kim TG, Lee HJ, Kim JH, Lim BH, Seo JW, Kang EM, Lee BU, Ahn YM, Roh YH, Nam SH, Kim BS.
    Lung Cancer; 2010 May 01; 68(2):248-52. PubMed ID: 19647333
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Weekly paclitaxel combined with monthly carboplatin in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study.
    Pujol JL, Milleron B, Molinier O, Quoix E, Depierre A, Breton JL, Gervais R, Debieuvre D, Hominal S, Namouni F, Tonelli D.
    J Thorac Oncol; 2006 May 01; 1(4):328-34. PubMed ID: 17409879
    [Abstract] [Full Text] [Related]

  • 19. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel.
    Hensing TA, Peterman AH, Schell MJ, Lee JH, Socinski MA.
    Cancer; 2003 Aug 15; 98(4):779-88. PubMed ID: 12910523
    [Abstract] [Full Text] [Related]

  • 20. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.
    Belani CP, Brodowicz T, Ciuleanu TE, Krzakowski M, Yang SH, Franke F, Cucevic B, Madhavan J, Santoro A, Ramlau R, Liepa AM, Visseren-Grul C, Peterson P, John WJ, Zielinski CC.
    Lancet Oncol; 2012 Mar 15; 13(3):292-9. PubMed ID: 22336221
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.